Safety Study of an Original Mesenchymal Stromal Cell Secretome-Based Medicinal Product for Spermatogenesis Restoration

SCIENTIFIC RELEVANCE. Currently, there are no effective and safe medicinal products for idiopathic male infertility. Previous studies in two animal models of infertility (short-term cryptorchidism in rats and doxorubicin-induced testicular injury in mice) have shown the effectiveness of an originator medicinal product based on the mesenchymal stromal cell (MSC) secretome.

AIM. The aim of the study was to evaluate the toxicity profile of the MSC secretome-based medicinal product in rats after local intratesticular or intramuscular administration.

MATERIALS AND METHODS. The MSC secretome is a combination of factors secreted by MSCs in low-glucose Dulbecco’s modified Eagle’s medium (DMEM-LG) for MSC conditioning. In the single-dose toxicity study, the MSC secretome-based medicinal product was injected under the testicular tunica albuginea of male Wistar rats (15 per group) at doses of 15 and 25 relative units (RU) per animal, which are 1.5 and 2.5 times higher than the therapeutic dose (10 RU). In the repeat-dose toxicity study, male Wistar rats (10 per group) received intramuscular thigh injections of the medicinal product on days 1, 6, and 12 at doses of 15 and 25 RU per animal. The local tolerance study involved histopathological examination of the testes and thighs at the injection site. All studies included control groups of intact animals and animals similarly injected with blank DMEM-LG. The early follow-up period was 14 days, and the late follow-up period was 42 days.

RESULTS. The rats showed no changes in the general condition after single and repeated doses of the MSC secretome-based medicinal product. Single subtunical doses induced moderate irritation; its signs included pathological changes in individual seminiferous tubules: epithelial atrophy (70% of the animals on day 14; 55% at late follow-up) and sperm stasis (70% of the animals). Similar changes were observed in the blank DMEM-LG group (up to 80% of the animals). There were no pathological changes in the tissues after repeated injections. A transient increase in alkaline phosphatase activity was detected in animals after their third intramuscular injection at a dose of 25 RU; the other biochemical parameters were normal in all study groups.

CONCLUSIONS. The MSC secretome-based medicinal product has a favourable safety profile following both intratesticular and intramuscular administration, as it does not cause any permanent changes in the studied organs and tissues.

1. Agarwal A, Baskaran S, Parekh N, Cho CL, Henkel R, Vij S, et al. Male infertility. Lancet. 2021;397(10271):319–33. https://doi.org/10.1016/S0140-6736(20)32667-2

2. Sagaradze G, Monakova A, Basalova N, Popov V, Balabanyan V, Efimenko A. Regenerative medicine for male infertility: a focus on stem cell niche injury models. Biomed J. 2022;45(4):607–14. https://doi.org/10.1016/j.bj.2022.01.015

3. Kharazi U, Badalzadeh R. A review on the stem cell therapy and an introduction to exosomes as a new tool in reproductive medicine. Reprod Biol. 2020;20(4):447–59. https://doi.org/10.1016/j.repbio.2020.07.002

4. Chen G, Kathrins M, Ohlander S, Niederberger C. Medical management of male infertility: now and future. Curr Opin Urol. 2023;33(1):10–5. https://doi.org/10.1097/MOU.0000000000001056

5. Ciccocioppo R, Cantore A, Chaimov D, Orlando G. Regenerative medicine: the red planet for clinicians. Intern Emerg Med. 2019;14(6):911–21. https://doi.org/10.1007/s11739-019-02126-z

6. Vieujean S, Loly JP, Boutaffala L, Meunier P, Reenaers C, Briquet A, et al. Mesenchymal stem cell injection in Crohn’s disease strictures: a phase I-II clinical study. J Crohns Colitis. 2022;16(3):506–10. https://doi.org/10.1093/ecco-jcc/jjab154

7. Chahal J, Gómez-Aristizábal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio A, et al. Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation. Stem Cells Transl Med. 2019;8(8):746–57. https://doi.org/10.1002/sctm.18-0183

8. Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020;143(12):3574–88. https://doi.org/10.1093/brain/awaa333

9. Monakova A, Sagaradze G, Basalova N, Popov V, Balabanyan V, Efimenko A. Novel potency assay for MSC secretome-based treatment of idiopathic male infertility employed Leydig cells and revealed vascular endothelial growth factor as a promising potency marker. Int J Mol Sci. 2022;23(16):9414. https://doi.org/10.3390/ijms23169414

10. Sagaradze GD, Basalova NA, Efimenko AY, Tkachuk VA. Mesenchymal stromal cells as critical contributors to tissue regeneration. Front Cell Dev Biol. 2020;8:576176. https://doi.org/10.3389/fcell.2020.576176

11. Kalinina N, Kharlampieva D, Loguinova M, Butenko I, Pobeguts O, Efimenko A, et al. Characterization of secretomes provides evidence for adipose-derived mesenchymal stromal cells subtypes. Stem Cell Res Ther. 2015;6:221. https://doi.org/10.1186/s13287-015-0209-8

12. Teixeira FG, Salgado AJ. Mesenchymal stem cells secretome: current trends and future challenges. Neural Regen Res. 2020;15(1):75–7. https://doi.org/10.4103/1673-5374.264455

13. Liu J, Ding Y, Liu Z, Liang X. Senescence in mesenchymal stem cells: functional alterations, molecular mechanisms, and rejuvenation strategies. Front Cell Dev Biol. 2020;8:258. https://doi.org/10.3389/fcell.2020.00258

14. Zhuang WZ, Lin YH, Su LJ, Wu MS, Jeng HY, Chang HC, et al. Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci. 2021;28(1):28. https://doi.org/10.1186/s12929-021-00725-7

15. Sagaradze G, Basalova N, Kirpatovsky V, Ohobotov D, Nimiritsky P, Grigorieva O, et al. A magic kick for regeneration: role of mesenchymal stromal cell secretome in spermatogonial stem cell niche recovery. Stem Cell Res Ther. 2019;10(1):342. https://doi.org/10.1186/s13287-019-1479-3

16. Sagaradze GD, Basalova NA, Kirpatovsky VI, Ohobotov DA, Grigorieva OA, Balabanyan VY, et al. Application of rat cryptorchidism model for the evaluation of mesenchymal stromal cell secretome regenerative potential. Biomed Pharmacother. 2019;109:1428–36. https://doi.org/10.1016/j.biopha.2018.10.174

17. Poshivalov VP. Pharmacoethology. St. Petersburg: Copy-Service; 1997 (In Russ.).

18. Muzhikyan AA, Makarova MN, Guschin YaA. Features histological processing of organs and tissues of laboratory animals. International Bulletin of Veterinary Medicine. 2014;(2):103–9 (In Russ.). EDN: SFLHTJ

19. Suckow MA, Weisbroth SH, Franklin CL, eds. The labo ratory rat. Elsevier; 2005. P. 929.

20. Dorato MA, Engelhardt JA. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul Toxicol Pharmacol. 2005;42(3):265–74. https://doi.org/10.1016/j.yrtph.2005.05.004